Substituting Generic Lamivudine for Emtricitabine in Virologically Suppressed HIV-Infected Patients.
PMID: 30189786
2018
Journal of correctional health care
Abstract: The two groups also showed similar values for CD4 counts, compliance, discontinuation, and M184V mutation; however, a slightly greater proportion of lamivudine patients experienced respiratory symptoms.
Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana.
Abstract: The most common NRTI mutation found was M184 V; K103 N and A98G were the most common NNRTI mutations seen.
Discussion: For the mothers who were on ART after prophylaxis in the PMTCT programme, the HIV-1 drug resistance associated mutations seen were dominated by M184 V for NRTIs and Thymidine Analogue-Associated Mutations (TAMS) including M41 L and T215Y; and K103 N with A98G for NNRTIs.
Discussion: However, in the other mothers in this group, M184 V occurred with Thymidine Analogue-Associated Mutations (
Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.
Result: The NRTI(t)-associated mutation M184 V/I emerged in 78.4% of the subtype B sequences and in 21.6% of the non-B subtype sequences (p = 0.009).
Discussion: After evaluating 184 genotyping tests from patients during the first virologic failure, we found a higher prevalence of subtype B, of the M184 V/I and K103 N mutations, as well as a high frequency of NRTI(t) and NNRTI-associated mutations, with no impact on virologic suppression.
Discussion: All the genotype sequences of the non-B subtype (F and BF) had the M184 V/I mutation, probably due to the high prevalence of this mutation and the very low frequency of non-B subtypes in our study.
Discussion: Similar to our results, the high prevalence of
Prevalence of HIV-1 pretreatment drug resistance among treatment naive pregnant women in Bissau, Guinea Bissau.
Abstract: Four carried mutations exclusively linked to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (K103N, K103N/S) and one carried mutations to both NNRTIs (G190S, K101E) and nucleoside reverse transcriptase inhibitors (NRTIs) (M184V).
Result: Four carried mutations towards NNRTI only (K103N and K103N/S) and one carried mutations to both NNRTI (G190S, K101E) and PMID: 30408827
2018
PloS one
Result: The M184V, K70R and K65R mutations induce high level resistance to NRTIs in recommended first-line regimen according to EACS (9.0).
Result: The thymidine analogue mutations (TAMs) M41L, K219Q and T215 revertants as well as the non-TAM M184V were among the most frequently transmitted NRTI-resistance mutations (>= 0.5%) (Table 4).
Table: M184V
Discussion: So far, resistance mutations selected by tenofovir and emtricitabine (K65R, K70R and M184V) have been rare (below 1%).
Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
Result: As expected, the number and type of mutations with frequencies > 20% (those within Sanger sequencing-based detection level) matched the cART history of the patient, e.g., the virus from patient SG28 had mutations associated with resistance to ABC (L74I 97.6% frequency), 3TC (M184V 99.7%), and EFV (K103N 98.8%, P225H 99.5%) and had been exposed to RTV, DRV, ABC, 3TC, and EFV; while patient SG86 had a virus with resistance to FTC (M184V 98.9%) and RAL (L74M 97.9%, E92Q 86.1% and T97A 99.8%) after being treated over the years with RTV, LPV, DRV, FTC, TDF, and RAL (Additional file 1: Table S1).
Result: Most of these minority drug resistance mutations were detected in the 67 cART-experienced individuals, e.g., the
Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.
Abstract: After switching to second-line ART, nine patients newly acquired the NRTI drug-resistant mutation, M184 V/I.
Discussion: Some reports indicate that the NRTI resistance mutation, M184 V, can enhance viral sensitivity to TDF, which could result in effective virus suppression.
Discussion: The Discussion: found that one patient newly acquired M184 V resistance mutations after 96 weeks second-line ART.
Discussion: show that TAM (M41 L, L210 W, and T215F/Y) and M184I/V mutations related to NRTI drug resistance increased after patients switched to the second-line regimen.
Long-term virological outcome in children receiving first-line antiretroviral therapy.
Result: M184V/I was present in 79% (41/52) of the children, and 27% (14/52) had Thymidine analog mutations (TAMs).
Result: DRM results were available for 3 of these children at 12th month and they had either M184V or M184I mutation in addition to K103N at this time point.
Discussion: Among those who developed VF, M184V, K103N, and Y181C were the most common DRMs observed as in South Africa.
Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
Discussion: Among 1943 individuals living with HIV in San Francisco who had at least one sequence reported to HIV surveillance from 2013-2017, 356 (18.3%) had an M184V mutation detected in at least one genotype, of whom 62 were not virally suppressed based on their most recent viral load (Personal communication, Mia Chen, SFDPH HIV surveillance, July 2, 2018).
Discussion: In San Francisco from 2014-2016, of 338 genotypes from individuals newly diagnosed with HIV, only three (0.89%) had a transmitted M184V mutation.
Discussion: In the U.S., approximately 0.4-1.05% of persons newly diagnosed with HIV have a virus with a transmitted M184V mutation.
Discussion: Of the six reported cases, five of the acquired viral strains had the M184V mutation in RT (Table 1), leading to high-level resistance to FTC.|mgd
HIV-1 subtype diversity, transmission networks and transmitted drug resistance amongst acute and early infected MSM populations from Coastal Kenya.
HIV mutation literature information.
PMID: 
2018
Journal of correctional health care
Browser Board
Co-occurred Entities
Filtrator
ViMRT